ABCL vs VRTX
AbCellera Biologics Inc. vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
64
Buy
VS
VRTX
Vertex Pharmaceuticals
64
Buy
| Metric | ABCL | VRTX |
|---|
| AI Score |
64
|
64
|
| Price |
$10.35
|
$525.88
|
| P/E Ratio |
-18.07×
|
30.58×
|
| ROE |
-15.1%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
86.0%
|
| Debt / Equity |
0.15×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
82.2
|
| Beta |
1.191
|
0.305
|
| Expected Upside |
—
|
+0.3%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus VRTX.
The committee scores are tied.
ABCL and VRTX both score 64/100.
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 82 is in overbought territory — Technical